<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178981</url>
  </required_header>
  <id_info>
    <org_study_id>BAT4217010</org_study_id>
    <nct_id>NCT03178981</nct_id>
  </id_info>
  <brief_title>E-cigarette Nicotine Pharmacokinetic Study</brief_title>
  <official_title>A Pharmacokinetic Study to Examine Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects During a Brief Period of ad Libitum Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British American Tobacco (Investments) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LA Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>British American Tobacco (Investments) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare nicotine delivery and product satisfaction in healthy subjects either&#xD;
      using several different types of electronic cigarettes or smoking a conventional cigarette.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma nicotine concentration (Cmax)</measure>
    <time_frame>-5, 1, 3, 5, 6, 7, 9, 15, 45, and 60 minutes relative to the first puff on the cigarette/e-cigarette</time_frame>
    <description>Nicotine pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nicotine concentration (Tmax)</measure>
    <time_frame>-5, 1, 3, 5, 6, 7, 9, 15, 45, and 60 minutes relative to the first puff on the cigarette/e-cigarette</time_frame>
    <description>Nicotine pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma nicotine concentration (AUC0-60)</measure>
    <time_frame>-5, 1, 3, 5, 6, 7, 9, 15, 45, and 60 minutes relative to the first puff on the cigarette/e-cigarette</time_frame>
    <description>Nicotine pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of puffs taken</measure>
    <time_frame>During 5 minute ad libitum puffing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective measurement of product satisfaction</measure>
    <time_frame>After 60 minute blood sampling period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mass loss from e-cigarette cartridge during puffing</measure>
    <time_frame>During 5 minute ad libitum puffing period</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Conventional cigarette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially-available combustible cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second-generation e-cigarette A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prototype second-generation (closed-tank) e-cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second-generation e-cigarette B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prototype second-generation (closed-tank) e-cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second-generation e-cigarette C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prototype second-generation (closed-tank) e-cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second-generation e-cigarette D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prototype second-generation (closed-tank) e-cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second-generation e-cigarette E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially-available second-generation (closed-tank) e-cigarette</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Use electronic cigarette or smoke conventional cigarette</intervention_name>
    <description>Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period</description>
    <arm_group_label>Conventional cigarette</arm_group_label>
    <arm_group_label>Second-generation e-cigarette A</arm_group_label>
    <arm_group_label>Second-generation e-cigarette B</arm_group_label>
    <arm_group_label>Second-generation e-cigarette C</arm_group_label>
    <arm_group_label>Second-generation e-cigarette D</arm_group_label>
    <arm_group_label>Second-generation e-cigarette E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Prior to study start, subjects must be current smokers of conventional factory-made&#xD;
             cigarettes (eCO &gt;10ppm at screening) who have either tried or are occasional users of&#xD;
             e-cigarettes. Subjects must be smoking ≥10 cigarettes per day and must have done so&#xD;
             for at least one year. Smoking status will be confirmed with a urinary cotinine level&#xD;
             of ≥200ng/ml (determined using NicAlert cotinine test kit) and an exhaled breath CO&#xD;
             level of &gt;10ppm (determined using a Smokerlyzer breath CO monitor) at screening, as&#xD;
             well as by tobacco use questionnaire.&#xD;
&#xD;
          2. Subjects will be males or non-pregnant, non-lactating females, and between 22 and 55&#xD;
             years of age inclusive. Age verification will be performed by checking of Federal or&#xD;
             state-issued ID (eg. passport or driving licence) during screening.&#xD;
&#xD;
          3. Women of child-bearing potential should be using one of the following acceptable&#xD;
             methods of contraception : combined (oestrogen and progestogen containing) oral,&#xD;
             intravaginal or transdermal hormonal contraception associated with inhibition of&#xD;
             ovulation; progestogen-only hormonal contraception, either oral, injected or&#xD;
             implanted, associated with inhibition of ovulation; progestogen-only oral hormonal&#xD;
             contraception where inhibition of ovulation is not the primary mode of action;&#xD;
             intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral&#xD;
             tubal occlusion; male or female condom with or without spermicide; cap, diaphragm or&#xD;
             sponge with spermicide.&#xD;
&#xD;
          4. Women of non-childbearing potential may be included if they are either surgically&#xD;
             sterile (hysterectomy and/or oophorectomy) or postmenopausal for more than 1 year and&#xD;
             must have a negative urine pregnancy test result during screening. Women who are&#xD;
             surgically sterile must provide documentation of the procedure by an operative report.&#xD;
&#xD;
          5. Male subjects must use an approved method of birth control during the entire study.&#xD;
             These subjects must not donate sperm during this time.&#xD;
&#xD;
          6. Subjects must be in good health, as judged by the PI or the appropriately qualified&#xD;
             designee based on medical history, ECG, vital signs, blood biochemistry, haematology,&#xD;
             urinalysis and physical examination.&#xD;
&#xD;
          7. Subjects must have a body mass index (BMI) between 18 and 30 kg/m2 inclusive. Male&#xD;
             subjects must have a weight between 60 and 120kg and female subjects between 50 and&#xD;
             100kg.&#xD;
&#xD;
          8. No clinically significant abnormalities in blood pressure values.&#xD;
&#xD;
          9. Subjects will have negative results for the urinary drug of abuse screening and&#xD;
             alcohol test.&#xD;
&#xD;
         10. Subjects will have given their written informed consent to participate in the study&#xD;
             and to abide by the study restrictions.&#xD;
&#xD;
        To be confirmed during each clinic visit:&#xD;
&#xD;
        1. Abstinence from tobacco and nicotine products will be confirmed by an exhaled breath CO&#xD;
        reading &lt;15ppm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have a history of, or clinically active significant, neurological,&#xD;
             gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic,&#xD;
             endocrine, haematological disease or other major disorders.&#xD;
&#xD;
          2. Subjects who have any clinically significant abnormal laboratory safety findings at&#xD;
             Screening and prior to first product use, as determined by the PI or the appropriately&#xD;
             qualified designee (1 repeat assessment is acceptable).&#xD;
&#xD;
          3. Subjects who have previously been diagnosed with any form of malignancy.&#xD;
&#xD;
          4. Subjects with significant allergies who in the opinion of the Principal Investigator&#xD;
             or appropriately qualified designee should not be included.&#xD;
&#xD;
          5. Subjects who have had an acute illness (e.g. upper respiratory tract infection, viral&#xD;
             infection, etc.) requiring treatment within 4 weeks prior to Admission.&#xD;
&#xD;
          6. Subjects who have used prescription or over-the-counter (OTC) bronchodilator&#xD;
             medication (e.g. inhaled or oral β-adrenergic agonists) to treat a chronic condition&#xD;
             within the 12 months prior to Admission.&#xD;
&#xD;
          7. Subjects with a recent history of or current drug or alcohol abuse who in the opinion&#xD;
             of the Investigator should not be included. Excessive intake of alcohol within the&#xD;
             last 6 months, defined as a regular maximum weekly intake of greater than 7 drinks for&#xD;
             women or 14 drinks for men. One drink is defined as one pint of regular beer (5%&#xD;
             alcohol), 200 ml of wine (12% alcohol), or 25 ml of distilled spirits (40% alcohol).&#xD;
&#xD;
          8. Subjects with an inability to communicate well with the Investigator/study staff&#xD;
             (i.e., language problem, poor mental development or impaired cerebral function).&#xD;
&#xD;
          9. Subjects who are participating in another clinical research study or who have&#xD;
             participated in a clinical research study in the last 2 months.&#xD;
&#xD;
         10. Subjects who have had treatment with prescription medications within 21 days or&#xD;
             over-the-counter medication within 24 hours of the planned first product use occasion,&#xD;
             except for those stated in the Inclusion Criteria. For all subjects, prescribed use of&#xD;
             blood pressure (beta blockers) and lipid lowering (statin) medications are permitted.&#xD;
&#xD;
         11. Subjects who have used any drugs or substances (except tobacco) known to be strong&#xD;
             inducers or inhibitors of any CYP enzymes (formerly known as cytochrome P450 enzymes)&#xD;
             within a 28 days period prior to first product administration. For a list of such&#xD;
             drugs and substances, please refer to&#xD;
             http://medicine.iupui.edu/clinpharm/ddis/main-table/.&#xD;
&#xD;
         12. Subjects who have had any treatment with smoking cessation medications (e.g.&#xD;
             Bupropion, Chantix or any NRT) within 30 days of the planned first product use&#xD;
             occasion.&#xD;
&#xD;
         13. Subjects with any other clinically significant medical history, in the Investigator's&#xD;
             opinion, including conditions which might affect drug absorption, metabolism or&#xD;
             excretion.&#xD;
&#xD;
         14. Female subjects, who are pregnant or become pregnant during the course of the study.&#xD;
&#xD;
         15. Subjects who have lost or donated more than 450ml of blood within the 2 months&#xD;
             preceding the first product administration.&#xD;
&#xD;
         16. Subjects who are self-reported non-inhalers (smokers who draw smoke from the cigarette&#xD;
             into the mouth and throat but who do not inhale). Subjects who are observed as&#xD;
             non-inhalers at Admission by the clinic staff will be excluded.&#xD;
&#xD;
         17. Subjects who are currently trying to stop smoking or to stop using e-cigarettes, or&#xD;
             considering stopping in the next two months. All subjects will be informed that they&#xD;
             are free to quit smoking/using e-cigarettes and withdraw from the study at any time.&#xD;
&#xD;
         18. Subjects who are unwilling or unable to comply with the study requirements.&#xD;
&#xD;
         19. Subjects who in the opinion of the Principal Investigator or their appropriately&#xD;
             qualified designee should not participate in the study for any other reason.&#xD;
&#xD;
        To be re-confirmed during each clinic visit:&#xD;
&#xD;
          1. Subject continues to meet all screening exclusion criteria. Pregnancy test to be&#xD;
             performed on all female subjects at each visit.&#xD;
&#xD;
          2. Receipt of any medication since screening visit that may have an impact on the safety&#xD;
             and objectives of the study (at the Principal Investigator's discretion).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Nides, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Clinical Trials</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

